Clinical pharmacokinetics of meloxicam - A cyclo-oxygenase-2 preferential nonsteroidal anti-inflammatory drug

被引:138
作者
Davies, NM [1 ]
Skjodt, NM
机构
[1] Univ Sydney, Coll Hlth Sci, Dept Pharmaceut, Sydney, NSW 2006, Australia
[2] Univ Calgary, Fac Med, Resp Res Grp, Calgary, AB, Canada
关键词
D O I
10.2165/00003088-199936020-00003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide] is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class which shows preferential inhibition of cyclo-oxygenase-2. Meloxicam has a plasma half-life of approximately 20 hours, making it convenient for once-daily administration. Meloxicam is eliminated after biotransformation to 4 pharmacologically inactive metabolites, which are excreted in urine and faeces. Meloxicam and its metabolites bind extensively to plasma albumin. Substantial concentrations of meloxicam are attained in synovial fluid, the proposed site of action in chronic inflammatory arthropathies. Neither moderate renal nor hepatic insufficiency significantly alter the pharmacokinetics of meloxicam. Dosage adjustment is not required in the elderly. Drug-drug interaction studies are available for some commonly co-prescribed medications. Concentration-dependent therapeutic and toxicological effects have yet to be extensively elucidated for this NSAID.
引用
收藏
页码:115 / 126
页数:12
相关论文
共 37 条
[1]  
ALBENGRES E, 1993, INT J TISSUE REACT, V15, P125
[2]   Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients with acute sciatica [J].
Auvinet, B ;
Ziller, R ;
Appelboom, T ;
Velicitat, P .
CLINICAL THERAPEUTICS, 1995, 17 (06) :1078-1090
[3]   Meloxicam in acute UV dermatitis - a pilot study [J].
Bayerl, C ;
Pagung, R ;
Jung, EG .
PHOTODERMATOLOGY PHOTOIMMUNOLOGY & PHOTOMEDICINE, 1998, 14 (5-6) :167-169
[4]  
Bevis PJR, 1996, BRIT J RHEUMATOL, V35, P56
[5]   Meloxicam pharmacokinetics in renal impairment [J].
BoultonJones, JM ;
Geddes, CG ;
Heinzel, G ;
Turck, D ;
Nehmiz, G ;
Bevis, PJR .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (01) :35-40
[6]   EFFECT OF FOOD ON PHARMACOKINETICS OF MELOXICAM, A NEW NON STEROIDAL ANTIINFLAMMATORY DRUG (NSAID) [J].
BUSCH, U ;
HEINZEL, G ;
NARJES, H .
AGENTS AND ACTIONS, 1991, 32 (1-2) :52-53
[7]  
BUSCH U, 1995, EUR J CLIN PHARMACOL, V48, P269
[8]   Interaction of Meloxicam with cimetidine, Maalox, or aspirin [J].
Busch, U ;
Heinzel, G ;
Narjes, H ;
Nehmiz, G .
JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 36 (01) :79-84
[9]  
BUSCH U, 1995, RHEUMATOL EUR, V24, P177
[10]   Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4 [J].
Chesné, C ;
Guyomard, C ;
Guillouzo, A ;
Schmid, J ;
Ludwig, E ;
Sauter, T .
XENOBIOTICA, 1998, 28 (01) :1-13